The University of Chicago Header Logo

Connection

Marina Chiara Garassino to Animals

Back to Details
This is a "connection" page, showing publications Marina Chiara Garassino has written about Animals.
Marina Chiara Garassino
Connection Strength
0.215
Animals
  1. Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. Clin Cancer Res. 2019 02 01; 25(3):989-999.
    View in: PubMed
    Score: 0.039
  2. Available evidence and new biological perspectives on medical treatment of advanced thymic epithelial tumors. Ann Oncol. 2015 May; 26(5):838-847.
    View in: PubMed
    Score: 0.030
  3. Emerging toxicities in the treatment of non-small cell lung cancer: ocular disorders. Cancer Treat Rev. 2014 Feb; 40(1):197-203.
    View in: PubMed
    Score: 0.027
  4. Development and clinical indications of cetuximab. Int J Biol Markers. 2007 Jan-Mar; 22(1 Suppl 4):S40-6.
    View in: PubMed
    Score: 0.017
  5. CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors. Nature. 2024 Nov; 635(8038):462-471.
    View in: PubMed
    Score: 0.015
  6. Caloric restriction and metformin selectively improved LKB1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy. J Exp Clin Cancer Res. 2024 Jan 02; 43(1):6.
    View in: PubMed
    Score: 0.014
  7. Myeloid cell heterogeneity in lung cancer: implication for immunotherapy. Cancer Immunol Immunother. 2021 Sep; 70(9):2429-2438.
    View in: PubMed
    Score: 0.012
  8. Immunometabolic Status of COVID-19 Cancer Patients. Physiol Rev. 2020 10 01; 100(4):1839-1850.
    View in: PubMed
    Score: 0.011
  9. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. Oncogene. 2018 12; 37(50):6463-6476.
    View in: PubMed
    Score: 0.010
  10. Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. Lung Cancer. 2018 06; 120:62-69.
    View in: PubMed
    Score: 0.009
  11. G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. J Thorac Oncol. 2016 07; 11(7):1170-5.
    View in: PubMed
    Score: 0.008
  12. Base excision repair-mediated resistance to cisplatin in KRAS(G12C) mutant NSCLC cells. Oncotarget. 2015 Oct 06; 6(30):30072-87.
    View in: PubMed
    Score: 0.008
  13. Across the universe of K-RAS mutations in non-small-cell-lung cancer. Curr Pharm Des. 2014; 20(24):3933-43.
    View in: PubMed
    Score: 0.007
  14. Targeting the MET gene for the treatment of non-small-cell lung cancer. Crit Rev Oncol Hematol. 2014 Feb; 89(2):284-99.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.